Release Tx to Showcase Advances in Sustained Therapeutic Protein Delivery to the CNS at the 8th CNS Drug Delivery Summit (10 November 2026)
Poster presentation to highlight latest preclinical data on the Myo-P4®, alongside the broader therapeutic potential of the Myo-P® platform
Campus Innovation Park, Geneva, Switzerland, 10 November 2026 / EIN Presswire: Release Therapeutics (“Release Tx” or “the Company”), a privately held Swiss BioMedTech company, today announced that it will showcase the Myo-P®, the Company’s proprietary encapsulated cell technology (ECT) platform for sustained therapeutic protein delivery to the central nervous system (CNS), at the 8th Annual CNS Drug Delivery Summit, taking place from 1 to 3 December 2026 in Boston, Massachusetts.
Release Tx’s abstract has been selected for the Summit’s Scientific Poster Session, where it will be presented by Delphine Knittel, PhD, Head of Operations at Release Tx, on Wednesday, 2 December 2026 at 14:40 EST.
About the Poster Presentation:
Abstract title: ‘Myo-P4, a CNS delivery system to treat Metachromatic Leukodystrophy (MLD)’
Presenting Author: Delphine Knittel, PhD, Head of Operations, Release Therapeutics SA
Date: Wednesday, 2 December 2026
Time: 14:40 EST
About the Myo-P® Platform
The Myo-P® is a modular encapsulated cell technology platform that combines genetically engineered, immortalised human myoblasts capable of sustained secretion of disease-specific therapeutic proteins with the Myo-Pod®, a patented, biocompatible hollow-fibre device no larger than a pin, which has been evaluated following subdural implantation in large-animal models and subcutaneous implantation in clinical studies. Release Tx’s current therapeutic focus is on rare paediatric genetic disorders affecting the CNS, with two programmes in development: the Myo-P4® for metachromatic leukodystrophy (MLD), in collaboration with the Paris Brain Institute, and the Myo-P5A® for Sanfilippo syndrome type IIIA (MPS IIIA), in collaboration with the University of Geneva (UNIGE).
The myoblast cell line has been engineered to produce a range of therapeutic proteins, including antibodies, enzymes and cytokines, with sustained protein secretion demonstrated in vivo for more than ten months.[i] The Myo-Pod device is cargo-agnostic, while the broader ECT has been evaluated following subdural, subcutaneous and peritumoural implantation, supporting its potential application across multiple therapeutic areas.[ii],[iii],[iv],[v] The Myo-P® platform is underpinned by a long IP runway and has received external validation through publications in Cell Press journals, competitive Innosuisse funding and the 2026 Disruptive Innovation Award from Geneva University Hospitals (HUG), while research using Release Tx’s licensed ECT earned researchers at HUG and the University of Geneva (UNIGE) the 2026 Pfizer Research Prize in Oncology.[vi],[vii],[viii]
About the Annual CNS Drug Delivery Summit
Organised by Hanson Wade, the annual CNS Drug Delivery Summit brings together leading experts from the pharmaceutical and biotechnology industries, academia and the investment community to explore advances in drug delivery to the central nervous system. The 2026 edition focuses on emerging technologies and strategies to overcome the blood-brain barrier, improve CNS exposure and accelerate development of next-generation therapies for neurological diseases. For more information, visit: https://cns-drug-delivery.com/
About Release Therapeutics
Headquartered in Geneva, Switzerland, Release Therapeutics is a privately held, BioMedTech company developing living implants to expand what is possible in the treatment of serious neurological diseases. Innovating at the nexus of Biotech and MedTech, the Company is advancing the Myo-P®, a pioneering cell macroencapsulation platform designed to enable sustained delivery of potent therapeutic proteins beyond the human blood-brain barrier. The technology integrates implantable macroencapsulation devices with an immortalised human myoblast cell line capable of producing a broad range of proteins for long-term delivery to the central nervous system. Release Therapeutics’ lead programme, the Myo-P4®, is in preclinical development for the treatment of metachromatic leukodystrophy (MLD), a rare genetic disorder that characterised by progressive loss of myelin and which typically affects young children.
For more information, please visit our website: https://www.release-tx.com/
Contacts
Release Therapeutics SA
KOJENT (for Release Therapeutics)
Dr. Jessica Kourniaktis
Phone: (+30)6932254679
Email: jkourniakti@kojent.co
References
[i] Lathuilière, A., et al. (2022). “Immortalized human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technology.” Molecular Therapy – Methods & Clinical Development, 26, 441–458. DOI: 10.1016/j.omtm.2022.07.017
[ii] Grogg, J., et al. (2023). “Engineering a versatile and retrievable cell macroencapsulation device for the delivery of therapeutic proteins.” iScience, 26(8), 107372. https://doi.org/10.1016/j.isci.2023.107372
[iii] Piguet, F., et al. (2025). “Encapsulated cell therapy demonstrated therapeutic efficacy in metachromatic leukodystrophy and sustained ARSA production in NHP.” Molecular Therapy, 33(4), ASGCT 28th Annual Meeting Abstracts, 1–1667. DOI: https://doi.org/10.1016/j.ymthe.2025.04.028
[iv] Vernet, R., et al. (2024). ‘A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors.’ Cancer Research Communications, 4(8), 2089–2100. DOI: https://doi.org/10.1158/2767-9764.CRC-24-0150
[v] Engel, A., et al. (2026). “Encapsulated cell therapy for local anti-CTLA-4 delivery in cancer immunotherapy.” iScience, 29(8), 116938. DOI: https://doi.org/10.1016/j.isci.2026.116938
[vi] Release Therapeutics. (2026, 22 October). “Release Therapeutics Secures Non-Dilutive Innosuisse Funding to Expand its Encapsulated Cell Technology Platform into Sanfilippo Syndrome Type IIIA.” Company press release. https://www.release-tx.com/post/release-therapeutics-secures-non-dilutive-innosuisse-funding-to-expand-its-encapsulated-cell-technol
[vii] Release Therapeutics. (2026, 23 October). “Release Therapeutics’ CNS-Targeted Encapsulated Cell Technology Wins 2026 Disruptive Innovation Award from Geneva University Hospitals.” Company press release. https://www.release-tx.com/post/release-therapeutics-cns-targeted-encapsulated-cell-technology-wins-2026-disruptive-innovation-awar
[viii] Foundation Pfizer Research Prize. (2026). “Inactivated tumor cells and capsules – a combined immunotherapy against cancer.” Pfizer Research Prize 2026, Oncology. https://www.pfizerresearchprize.ch/awardees-2026/research-projects/inactivated-tumor-cells-and-capsules-a-combined-immunotherapy-against-cancer
Comments